B. Riley assumed coverage on shares of Harrow Health (NASDAQ:HROW – Get Rating) in a research note released on Thursday, The Fly reports. The firm issued a buy rating and a $17.00 price objective on the stock.
Separately, TheStreet downgraded Harrow Health from a c- rating to a d+ rating in a research note on Thursday, May 19th.
Harrow Health Trading Up 0.4 %
NASDAQ:HROW opened at $9.08 on Thursday. The company has a quick ratio of 4.61, a current ratio of 5.01 and a debt-to-equity ratio of 13.36. Harrow Health has a 1-year low of $5.40 and a 1-year high of $12.99. The firm has a market capitalization of $245.80 million, a price-to-earnings ratio of -10.09 and a beta of 0.65. The stock has a fifty day simple moving average of $7.80 and a 200 day simple moving average of $7.22.
Institutional Investors Weigh In On Harrow Health
Several hedge funds have recently bought and sold shares of the business. Bailard Inc. lifted its stake in Harrow Health by 9.9% in the 2nd quarter. Bailard Inc. now owns 16,837 shares of the company’s stock worth $123,000 after acquiring an additional 1,515 shares in the last quarter. Prelude Capital Management LLC raised its stake in shares of Harrow Health by 3.1% during the 2nd quarter. Prelude Capital Management LLC now owns 97,819 shares of the company’s stock worth $712,000 after purchasing an additional 2,908 shares in the last quarter. Millennium Management LLC raised its stake in shares of Harrow Health by 2.1% during the 2nd quarter. Millennium Management LLC now owns 202,396 shares of the company’s stock worth $1,473,000 after purchasing an additional 4,257 shares in the last quarter. State Street Corp raised its stake in shares of Harrow Health by 5.5% during the 1st quarter. State Street Corp now owns 86,813 shares of the company’s stock worth $592,000 after purchasing an additional 4,521 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Harrow Health by 14.1% during the 4th quarter. First Trust Advisors LP now owns 39,277 shares of the company’s stock worth $339,000 after purchasing an additional 4,865 shares in the last quarter. 59.83% of the stock is owned by hedge funds and other institutional investors.
Harrow Health Company Profile
Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
- Get a free copy of the StockNews.com research report on Harrow Health (HROW)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.